Thursday 3 February | |
BT Group PLC | Q3 Results |
Compass Group PLC | Q1 Results |
Cranswick PLC | Q3 Results |
Renishaw PLC | Half Year Results |
Shell PLC | Full Year Results |
UK Commercial Property REIT Ltd | Trading Statement |
Virgin Wines UK PLC | Trading Statement |
Friday 4 February | |
Airtel Africa PLC | Q3 results |
SSP Group PLC | Trading Statement |
Monday 7 February | |
K3 Capital Group PLC | Half Year Results |
Lamprell PLC | Trading Statement |
Lok'nStore Group PLC | Trading Statement |
Brown Advisory US Smaller Cos PLC | Half Year Results |
Tuesday 8 February | |
Alumasc Group PLC | Half Year Results |
Bellway PLC | Trading Statement |
BP PLC | Full Year Results |
DCC PLC | Trading Statement |
Mattioli Woods PLC | Half Year Results |
Micro Focus International PLC | Full Year Results |
Ocado Group PLC | Full Year Results |
SSE PLC | Trading Statement |
Wednesday 9 February | |
Barratt Developments | Half Year Results |
Discoverie Group PLC | Q3 Results |
Dunelm Group PLC | Half Year Results |
GlaxoSmithKline PLC | Full Year Results (at 1200 GMT) |
Grainger PLC | Trading Statement |
PZ Cussons PLC | Half Year Results |
Smurfit Kappa Group PLC | Full Year Results |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
Read more